Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Debt to Equity (2023 - 2025)

Xeris Biopharma Holdings' Debt to Equity history spans 3 years, with the latest figure at $16.1 for Q4 2025.

  • For the quarter ending Q4 2025, Debt to Equity rose 305.37% year-over-year to $16.1, compared with a TTM value of $16.1 through Dec 2025, up 305.37%, and an annual FY2025 reading of $16.1, up 305.37% over the prior year.
  • Debt to Equity for Q4 2025 was $16.1 at Xeris Biopharma Holdings, up from -$254.9 in the prior quarter.
  • The five-year high for Debt to Equity was $16.1 in Q4 2025, with the low at -$254.9 in Q3 2025.
  • Average Debt to Equity over 3 years is -$26.05, with a median of -$0.11 recorded in 2024.
  • Biggest YoY gain for Debt to Equity was 305.37% in 2025; the steepest drop was 51905.27% in 2025.
  • Tracing XERS's Debt to Equity over 3 years: stood at -$28.15 in 2023, then surged by 72.16% to -$7.84 in 2024, then surged by 305.37% to $16.1 in 2025.
  • Per Business Quant, the three most recent readings for XERS's Debt to Equity are $16.1 (Q4 2025), -$254.9 (Q3 2025), and -$11.33 (Q2 2025).